Pfizer made billions by treating symptoms. Traders lose billions by doing the same. This piece shows the brutal overlap, and ...

The health impact of a Covid infection was higher than the risks from the vaccine for teens and children - but it won't settle arguments over current vaccine policy ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

A Pfizer-BioNTech COVID-19 vaccine vial. The Baker-Polito administration announced in a state press release Friday that Massachusetts residents 65 years of age or older and those with vulnerabilities ...

Last year, a cross-party group of 21 MPs and peers expressed alarm about 'growing public and professional concerns' over the ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them. Approval of ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker Metsera. Novo is now offering to pay as much as $10 billion for the company, Metsera ...

It's officially the season of text prompts and phone call reminders to get your seasonal vaccines. Cases of flu, RSV, COVID-19, and other common respiratory illnesses tend to spike as temperatures go ...